Overview
GILD market data
Price History
GILD price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for GILD. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Gilead Receives EMA CHMP Recommendation For Authorization For Trodelvy Plus Keytruda To Treat Metastatic Triple-Negative Breast CancerBenzinga · Jul 24, 2026, 10:29 AM
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?Benzinga · Jul 24, 2026, 10:25 AM
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?The Motley Fool · Jul 23, 2026, 8:15 PM
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are UnderratingThe Motley Fool · Jul 22, 2026, 11:00 AM
Gilead Sciences shares are trading lower after Leerink Partners downgraded its rating on the stock from Outperform to Market Perform and lowered its price target from $146 to $127.Benzinga · Jul 21, 2026, 6:07 PM
Gilead, Merck Advance Potential Blockbuster Weekly HIV PillBenzinga · Jul 21, 2026, 5:28 PM
Leerink Partners Downgrades Gilead Sciences to Market Perform, Lowers Price Target to $127Benzinga · Jul 21, 2026, 4:42 PM
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various IndexesGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading WarningsBenzinga · Jul 16, 2026, 5:29 PM
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS InsiderGlobenewswire Inc · Jul 15, 2026, 3:15 PM